Drug Trial Radar · NCT05009329
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
Last checked: Nov 20, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
315
Actual
Start
Jul 26, 2021
Primary completion
Aug 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Allist Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 17, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To assess safety, tolerability, PK, efficacy and determine recommended phase 2 dose (RP2D) of JAB-21822 (glecirasib) administered in adult participants with KRAS p.G12C-mutant advanced solid tumors.
Conditions
- NSCLC
- Solid Tumor
Interventions
JAB-21822Drug
JAB-21822 will be administered orally
JAB-21822Drug
JAB-21822 will be administered orally
JAB-21822Drug
JAB-21822 will be administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of dose limiting toxicities (DLTs) in the dose escalation phaseTime frame: first 21 days
- Number of participants with adverse eventsTime frame: up to 3 years
- Overall response rate (ORR) by IRC (independent review committee)Time frame: up to 3 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.